WHO Approves Vaccine for Adolescents Amid Global Health Developments

Recent health news highlights include WHO's approval of an mpox vaccine for adolescents, $1 billion in WHO budget pledges, France's demand for job guarantees from Sanofi, and Baxter's IV fluid import amidst a U.S. shortage. Additional reports cover Vanda Pharmaceuticals' rejection of a takeover bid and Blue Cross Blue Shield's $2.8 billion antitrust settlement.

The World Health Organization has given green light to Bavarian Nordic's mpox vaccine for adolescents aged 12 to 17, marking a significant step in safeguarding this vulnerable age group. The authorization comes as part of the WHO's efforts to address global health concerns, particularly during widespread outbreaks.

At a recent event in Berlin, the WHO announced receiving $1 billion in pledges for its upcoming budget cycle. WHO Head Dr. Tedros Ghebreyesus emphasized the critical nature of such investments, highlighting how recent global health crises reveal their impacts on broader societal stability.

Meanwhile, financial moves continue to shape the pharmaceutical sector. France seeks job assurances from Sanofi regarding its painkiller production, and Baxter turns to international imports to stave off a U.S. medical product shortage caused by Hurricane Helene.

(With inputs from agencies.)